Siewert Type 1 GEJ Cancer clinical trials at UCLA
1 in progress, 0 open to eligible people
Showing trials for
Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Sorry, not currently recruiting here
This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors.
Santa Monica, California and other locations
Our lead scientists for Siewert Type 1 GEJ Cancer research studies include Rosen Lee.
Last updated: